The University of Southampton
University of Southampton Institutional Repository

Recommendations on treatment for IPF

Recommendations on treatment for IPF
Recommendations on treatment for IPF
Patient management in Idiopathic Pulmonary Fibrosis (IPF) is largely based on societal guidelines and recommendations. A recent update by the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS) and Latin American Thoracic Association (ALAT) provided updated guidance on the diagnosis and management of IPF, along with recommendations on pharmacologic and non-pharmacologic approaches to patient management. The treatment guidance is based on GRADE criteria, which rates the quality of evidence according to previously published methodology. Here we discuss how to interpret the recent guideline updates and the implications of this guidance for clinical practice. In addition we discuss the assessment and recommendations for a number of pharmacological agents that have been the focus of clinical trials over the past years. Although no single pharmacological agent was recommended by the guidelines committee, we discuss how since then, more recent data have resulted in the approval of pirfenidone in Europe, and preliminary negative findings regarding the safety of a triple therapy regimen consisting of prednisone, azathioprine and N-acetylcysteine have raised the question of whether it is no longer a treatment option. As clinicians, we must interpret the available guidance and recommendations as we consider each individual patient and as we discuss the available clinical data and the patient's own preferences in our approach to the management of this disease.
1465-9921
S6
Behr, Jürgen
c87301f1-90b1-4ca0-8ea8-e83566e18431
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Behr, Jürgen
c87301f1-90b1-4ca0-8ea8-e83566e18431
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26

Behr, Jürgen and Richeldi, Luca (2013) Recommendations on treatment for IPF. Respiratory Research, 14, supplement 1, S6. (doi:10.1186/1465-9921-14-S1-S6). (PMID:23734936)

Record type: Article

Abstract

Patient management in Idiopathic Pulmonary Fibrosis (IPF) is largely based on societal guidelines and recommendations. A recent update by the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS) and Latin American Thoracic Association (ALAT) provided updated guidance on the diagnosis and management of IPF, along with recommendations on pharmacologic and non-pharmacologic approaches to patient management. The treatment guidance is based on GRADE criteria, which rates the quality of evidence according to previously published methodology. Here we discuss how to interpret the recent guideline updates and the implications of this guidance for clinical practice. In addition we discuss the assessment and recommendations for a number of pharmacological agents that have been the focus of clinical trials over the past years. Although no single pharmacological agent was recommended by the guidelines committee, we discuss how since then, more recent data have resulted in the approval of pirfenidone in Europe, and preliminary negative findings regarding the safety of a triple therapy regimen consisting of prednisone, azathioprine and N-acetylcysteine have raised the question of whether it is no longer a treatment option. As clinicians, we must interpret the available guidance and recommendations as we consider each individual patient and as we discuss the available clinical data and the patient's own preferences in our approach to the management of this disease.

Full text not available from this repository.

More information

Published date: 16 April 2013
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 369097
URI: https://eprints.soton.ac.uk/id/eprint/369097
ISSN: 1465-9921
PURE UUID: 558c5826-52fa-45a6-80db-4cf48d4a76a7

Catalogue record

Date deposited: 24 Sep 2014 12:42
Last modified: 18 Jul 2017 01:40

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×